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Angiogenesis is a central cancer hallmark, necessary for supporting tumor growth and metastasis. In vivo imaging
of angiogenesis is commonly applied, to understand dynamic processes in cancer development and treatment
strategies. However, most radiological modalities today assess angiogenesis based on indirect mechanisms, such
as the rate of contrast enhancement after contrast agent administration. We studied the performance of raster-
scan optoacoustic mesoscopy (RSOM), to directly reveal the vascular network supporting melanoma growth
in vivo, at 50 MHz and 100 MHz, through several millimeters of tumor depth. After comparing the performance at
each frequency, we recorded, for the first time, high-resolution images of melanin tumor vasculature development
in vivo, over a period of several days. Image validation was provided by means of cryo-slice sections of the same
tumor after sacrificing the mice. We show how optoacoustic (photoacoustic) mesoscopy reveals a potentially
powerful look into tumor angiogenesis, with properties and features that are markedly different than other
radiological modalities. This will facilitate a better understanding of tumor’s angiogenesis, and the evaluation of
treatment strategies.
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Imaging of tumor growth, tumor dynamics, and tumor angiogenesis
is important in elucidating tumor biology and physiology [1,2], and
understanding the tumor microenvironment [3,4]. Tomographic
systems, such as positron emission tomography (PET) [5], magnetic
resonance imaging (MRI) [6], or fluorescence molecular tomography
(FMT) [7], have been employed to resolve vasculature and
angiogenesis. However, these modalities do not directly resolve the
vascular bed. PET and FMT reveal vasculature based on contrast-
enhanced low resolution images. The enhancement is achieved by
blood-pool agents, essentially radio-isotopes or fluorochromes that are
restrained in the vascular system. Optical tomography methods can in
principle, directly resolve the absorption of blood vessels, without the
need for contrast agents; however, the low resolution achieved, and
the mixed contributions of absorption and scatter, deterred its wide-
use for imaging angiogenesis. The resolution of these systems does not
exceed 1 mm, even when small animals are considered. Therefore
only bulk measures of the vascular bed are assessed.
MRI offers higher resolution, but similarly to other radiological
methods, does not directly resolve the vasculature. Instead,angiogenesis can be indirectly assessed through arterial spin labeling
(ASL), or blood oxygenation level-dependent (BOLD) [8]. Dynamic
contrast-enhanced (DCE)-MRI is considered as a more direct method
for measuring angiogenesis [8–10], but it generally visualizes bulk
effects present after enhancement by a contrast agent and not
individual small vessels. To image smaller vessels, micro-MRI could
be used [11], but it is so far better suited for ex-vivo studies. Similarly,
ultrasound imaging is not sensitive in visualizing small blood vessels.
Contrast enhanced volumetric X-ray CT (VCT) has been also
considered for vasculature imaging, yielding visualization of blood
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[12]. Complication of this technique include the use of ionizing
radiation, and the administration of contrast agents which are not well
tolerated in longitudinal studies [13].
While bulk measures of angiogenesis offer useful insights in
assessing anti-angiogenic treatment, the ability to visualize at higher
resolution is a sought after target as it allows a better insight into the
architecture, and the dynamic evolution of the vascular network
supporting tumor growth and metastasis. Images of individual
venules and arterioles can be achieved by optical microscopy
techniques, such as multiphoton microscopy [14], applied in-vivo.
Intravital microscopy has enabled high-resolution angiogenesis
insights [2], revealing important details on the structural and
functional alterations of blood vessels, better explaining the tumor
micro-environment and the successes or failures of different treatment
strategies. Optoacoustic (photoacoustic) microscopy has also dem-
onstrated potential for imaging vasculature in high-resolution and
in-vivo[15,16]. The natural label-free contrast mechanism of optoa-
coustic methods is the absorption of light. As hemoglobin is a major
absorber of light in the visible, and the near-infrared regions, blood
vessels, containing concentrated hemoglobin, can be accurately
resolved by optoacoustic methods [17]. However, the caveat of
optical microscopy methods is that only a small fraction of the tumor
is typically visualized [18,19]. While mosaicking techniques are
available to reveal a larger field of view, it is not possible to penetrate
highly scattering tissues, such as malignant tumors and surrounding
tissues, much deeper than a few hundred microns. Therefore the
information obtained with these methods, is only a partial picture
of the tumor environment. Moreover, many intravital approaches
require an optical window, surgically placed on the tumor; an
invasive procedure, which also provides a partial view of the tumor
microenvironment [20]. Optical coherence tomography, implemen-
ted in the frequency domain, has been also employed for imaging
vasculature in the tumor microenvironment [21], but it was capable
of imaging vessels up to a depth of only ~1 mm so far.
Even though optoacoustic microscopy based on optical focusing, is
limited by depth, optoacoustic signals based on ultrasound focusing,
are highly scalable and enable penetration through several millimeters
to centimeters of tissue. In this case, resolution can be exchanged with
penetration depth; i.e. the higher the resolution the more superficial
the imaging. Although a precise relationship between resolution and
depth is difficult to establish, as it depends on multiple system and
tissue parameters, optoacoustic imaging at frequencies on the order
of 20 to 30 MHz have achieved resolutions of 70 to 100 μm [22]. In
these images, only large vessels of minimum apparent diameter of
81 μm have been observed [22].
In this work we showcase how an emerging optoacoustic
implementation termed raster-scan optoacoustic mesoscopy
(RSOM), can be employed to break through the limits of current
methods of tumor angiogenesis imaging, and provide high-resolution
optoacoustic mesoscopy of tumor vasculature. We investigate how
frequency and band, affect the imaging ability by implementing
RSOM at 50 MHz central frequency (RSOM 50), and 100 MHz
central frequency (RSOM 100). Both these implementations lead to
ultra-wide band measurements, for example the RSOM100 imple-
mentation has an ultrasound frequency bandwidth of approximately
160 MHz. This presents a unique inversion problem, which is
addressed herein using a novel frequency-dependent inversion, shown
necessary for optimally accommodating the broad bandwidth of themeasurements. This technological progress leads to new, previously
not reported, performance in resolving tumor vasculature reaching
better than 5 μm axial resolution, and better than 20 μm lateral
resolution through at least 3 mm of tissue depth. We discuss the
implications of these new features in better understanding tumor
angiogenesis at the entire tumor level
Materials and Methods
Imaging studies were based on a home built RSOM system,
previously described by Omar et al. [23,24]. In epi-illumination
mode, the technique has yielded 4 μm axial and 18 μm lateral
resolution in tissue mimicking phantoms, through several millimeters
of depth [24]. Figure 1 shows the system, which is based on
spherically focused, high-frequency ultrasound detectors, with both
50 MHz, and 100 MHz central frequency. The 50 MHz detector has
an active aperture diameter of 3 mm, an f-number of 0.99, and a
bandwidth of 10 to 90 MHz, while the 100 MHz detector has an
active aperture of 1.5 mm, an f-number of 1.1, and a bandwidth of 20
to 180 MHz. The excitation is based on a fast, nano-second laser,
operating at 532 nm, and with a pulse repetition frequency of 2 kHz
(Wedge HB532, Bright Solutions SRL, Pavia, Italy). The measured
signals are amplified by a low noise amplifier with a gain of 63 dB
(AU-1291, Miteq Inc., USA), and subsequently acquired with a
sampling frequency of 1GSps (EON-121-G20, Gage-applied,Montreal,
Canada). The raster-scanning is performed in a continuous-discrete
manner to expedite the measurements; the step sizes are 8 μm for
RSOM100 and 15 μm for RSOM50 [23,24].
To examine the capacity of the system in resolving tumor
angiogenesis, B16F10 melanoma cells (0.5 × 106 cells in 25 μl PBS
solution) were injected subcutaneously into the mammary fat pad of
four 8 weeks old female Hsd:Athymic Nude-Foxn1nu mice.
Melanoma tumor growth and vascular changes were monitored
over a time course of 8-9 days. Each animal was scanned up to three
times, with an additional final scan directly before euthanasia.
For the in vivo experiments, a custom-made mouse bed was
designed, shown in Figure 1A. The bed was slightly curved, increasing
in height towards the headpiece, to keep the animal’s head above
water. During the experiment the mice lay on their back with a
boundary on the sides of the bed to hold them in position. The ROI
around the tumor side was covered by a thin plate, made of acrylic
glass, with a 2 × 2 cm opening in the center. The opening was sealed
with a thin plastic membrane and coupled to the mouse skin above
the ROI with ultrasound gel. The mouse bed was immersed in warm
water, covering the ROI by several millimeters and the body
temperature was maintained at 36°C. The mice were imaged under
1.8% isoflurane anesthesia. All procedures were approved by the
District Government of Upper Bavaria.
For reconstruction, three-dimensional beamforming with a
dynamic aperture was used [23,24]. Because of the ultra-wide
bandwidth of the employed detectors, we divided the reception
bandwidth into several smaller sub-bands [24,25]. In this way, images
are reconstructed using a sequential narrow band inversion (SNBI),
which inverts the low frequencies separately from the high
frequencies. In this work a 2-band split was performed; however, a
finer band reconstruction can be implemented. The advantage of
SNBI is that each frequency band is reconstructed with parameters
better suited to the signal-to-noise characteristics of the band. By also
rendering the different bands reconstructed in different colors [24],
on the same final image, the resulting image allows for a better
Figure 1. (A) Depiction of the raster scan system, showing the position of the mouse, the mouse bed, anaesthesia, the detector, and the
illumination, (B) depiction of the two lateral profiles through a 3 μm sphere, characterizing the resolution of RSOM100, and (C) profiles
through a 10 μm sphere characterizing resolution of RSOM50.
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their masking by the low frequencies on the final reconstruction. To
assure that no ringing effects appear from filtering, we divided the
frequencies in such a way, that the relative bandwidth was kept








In case of the 100 MHz detector, we divided the reception
bandwidth into 2 sub-bands with 100% relative bandwidth, a similar
procedure was applied to the 50 MHz detector. After choosing the
value of the relative bandwidths, and the first cutoff frequency, the





Throughout this work, we applied a color map where red represents
the reconstruction of the low frequencies, 20 to 60MHz for RSOM100,
and 10 to 30 MHz for RSOM50, and green represents high frequencies,
60 to 180 MHz for RSOM100 and 30 to 90 MHz for RSOM50.
For validation purposes we used our prototype imaging cryo-
microtome [26,27]. Reflection (RGB), and Fluorescence (740/780
exc/emm wavelengths) imaging were acquired resulting in a
multispectral volume with voxel dimensions of ~25 × 25 × 50 μm.
Results and Discussion
To compare the performance of the two different detectors, we show
in Figure 1, B and C lateral profiles through a 3 μm sphere forRSOM100, and through a 10 μm sphere for RSOM50 (both are
polybead black dyed microspheres, Polysciences Inc., Warrington,
PA, USA), the calculated full width at half maximum (FWHM) of the
profiles is 18 μm, and 45 μm respectively.
Figure 2, A and B, shows a zoom into a vascular network recorded
with the two systems. In Figure 2C, a profile of the vessels marked by
the arrow in Figure 2, A and B, is shown and the FWHM is
calculated. With RSOM50 and RSOM100, we obtain lateral
resolutions of 42.5 μm and 20 μm, respectively, which corresponds
well to the characterization using the microspheres in Figure 1.
For direct comparison of the two different detectors, we show in
Figure 2, D and E the same ROI at Day 4 after melanoma cell
injection acquired with the 100 MHz and the 50 MHz detector.
Figure 2, D and E shows a black hole where the tumor is located. The
vasculature around the tumor can be clearly identified, however
showing some discontinuities, which could be attributed, to the
higher f-number, and thus the lower angle of acceptance, of the 100
MHz detector. Thus, long tilted structures, such as vessels, which
generate an optoacoustic wave normal to them, i.e. oblique to the axis
of the detector will not be detected. In Figure 2E, we clearly observe
an improved image quality, where vessels appear as continuous
structures, the appearance of additional vasculature in Figure 2E
compared to Figure 2D is attributed, to the best of our knowledge, to
the lower f-number, i.e. higher angle of acceptance, of the 50 MHz
detector, thus even some of the tilted vasculature could be observed.
In Figure 3, tumor growth over time is followed, the images were
measured using RSOM50. For better visualization, a partial MIP of
the reconstruction is taken, where instead of taking the MIP of the
whole volume we rather start at a depth of ~900 μm below the surface
Figure 2. Comparison of the imaging performance achieved by RSOM100 and RSOM50 imaging the vasculature of a melanoma tumor. An
ROI of 3mm×3mmwas acquiredwith A) RSOM100, and B) RSOM50. C) Lateral profile through the vesselsmarked by the green arrow in A
and B). D and E)MIPs of the sameROI around the tumor at Day 4 after tumor cell injection. D) In RSOM100, the center of the tumor showsup
as a black hole. E) In RSOM50, the vasculature appears as a continuous network. (Scale bars: A and B: 500 μm, d and e: 1 mm).
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the vessels around the tumor, as well as the growth of new vessels due
to angiogenesis, are observed on the same image. Additionally, the
inset in every subfigure of Figure 3 shows a zoom-in on the same area,
through all the days, from a location in the proximity of the tumor.
From the sub-figures the growth of the tumor, represented by the
growth of the black non-vascularized spot, indicated by a thick arrow,
is observed. Additionally, in the inset it is observed that upon
interaction with the tumor, the two big vessels, a thick arrow points to
that region, start re-arranging, while at the same time, smaller vessels
start growing in that region. Due to tumor growth, the flexibility of
skin and differences in fixing the tumor location through the different
days, it is not possible to show the exact same ROI in all the
subfigures of Figure 3.
Figure 4 shows a volumetric representation of a tumor imaged at
Day 9, which was validated by cryo-slices. In Figure 4(a), a maximum
intensity projection (MIP) of the ROI from 930 μm to a depth of
2115 μm away from the focus is shown. The tumor itself shows up as
a dark area, because the melanin-rich tumor strongly absorbs visible
laser light already in the upper layers, and high-frequency detectors
cannot detect the extremely low frequencies generated from the
tumor bulk, on the order of 0.1 to 1 MHz. Figure 4A correlates well
with the cryo-slice taken at a depth of 930 μm, as shown in Figure 4E.
In Figure 4, B–D, a MIP of the ROI from 615 μm, 390 μm, 0 μm to
a depth of 2115 μm are shown, visualizing the feeding vessels of the
tumor. Figure 4, B and C correlate well to the corresponding cryo-slices shown in Figure 4, F and GFigure 4H shows a volumetric
image of the ROI. The tumor appears as a bump on this image, with
vasculature surrounding it.
Conclusions
We demonstrated imaging of tumor growth, the corresponding
arrangement of the surrounding vascular network, and the growth of
new micro-vasculature in the vicinity of the tumor using ultra-
wideband raster-scan optoacoustic mesoscopy (RSOM). To the best
of our knowledge, this is the first time that tumor vasculature is
imaged at such depths with such resolution in-vivo. We showed that
RSOM could be applied longitudinally and resolve growth-related
changes of the same tumor.
In this work, we compared the performance of RSOM
implementation at 50 MHz and 100 MHz. The images obtained
show that imaging using the 100 MHz detector results to measurable
improvements in image ability by resolving smaller structures, such as
the newly sprouting vessels, especially when implemented with multi-
frequency reconstruction, so that the high frequencies are not masked
by low frequencies [24,25]. On the other hand, as expected, the
50 MHz detector performs better in imaging larger structures generating
lower frequencies, such as large blood vessels (larger than 50 μm in
diameter), thus most of the vasculature are better seen with the 50MHz
detector. Additionally, the smaller f-number (i.e. higher angular
coverage) of the 50 MHz detector performs better in imaging oblique
vessels, thus the vasculature appears more continuous in RSOM50
Figure 3. Tumor growth over time. Images of the tumor area were acquired at Day 2, Day 4, Day 7, and Day 9 after injection of the
melanoma cells, the thick arrow points to the tumor. The images are generated by taking the maximum intensity projection of the tumor
from a depth of 900 μm from the surface of the tumor. The inset in every image, shows the same region, from an area very close to the
tumor, and shows two large vessels (the arrow points to that region), between which small vessels grow over time. (Scale bar: 1 mm in
the images, 0.5 mm in the inset.)
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that do not appear with the 100 MHz detector, could be more
efficiently measured with the 50 MHz detector, as seen in Figure 2.
Because of this, the data from RSOM100 could be used in a hybrid
implementation together with RSOM50 to offer a more complete
picture of the tumor micro-vasculature. RSOM100 could be used to
image the tumor in the first days of development, or image the small
sprouting micro-vessels, and RSOM50 could provide complementary
information especially as tumor structures and vessels become larger
as a function of tumor growth. In this case image processing, and
image co-registration tools could be employed to merge together the
images collected at the different spectral bands.
Applying multi-frequency reconstruction improves the visibility of
the small structures, i.e. structures corresponding to high frequencies,
such as the newly sprouting vessels during angiogenesis. Because the
amplitude of the signals is proportional to the size of the object
generating those signals, the high-frequencies generally have a lower
SNR compared to the low frequencies. Additionally high-frequencies
are more strongly attenuated than low frequencies, thus if all the
frequencies are simultaneously reconstructed, the high-frequencies
will be masked by the low frequencies. By processing the high-
frequencies separately, it is possible to process them better, and
subsequently improve the visibility for small structures [24].The obtained capabilities should enable a better understanding of
tumor growth, and tumor angiogenesis, which is important in
understanding tumor’s physiology, mechanisms of metastasis, and
planning of therapy, where RSOM is capable of imaging tumor’s
growth, tumor’s angiogenesis, and theoretically tumor’s response to
various kinds of therapy. This specifically applies to those kinds of
therapies that affect tumor vasculature, target tumor angiogenesis,
and which are based on enhanced permeability and retention (EPR)
[3,4]. This could be applied not only to pre-clinical research, but also
in clinical environments, such as skin imaging [25].
Finally, further technological advances, such as advances in laser
technology, illumination configuration [28], and detection technol-
ogy, would enable better imaging capabilities for RSOM. For instance
by using additional laser lines in RSOM, not only anatomical images
could be generated, but also functional images visualizing tumor
metabolism, oxygenation maps and hypoxia regions inside the tumor
could be obtained. Additionally, applying smart algorithms to this
multispectral data will improve the detection sensitivity [29]. Using
point ultrasonic detectors, (e.g. waveguide Bragg grating (WBG)
[30]) with a broad, flat bandwidth will improve the detection of
lower and higher frequencies, as well as the angular coverage of the
detector, and thus enable miniaturization of the system, and multi-
scale imaging.
Figure 4. Volumetric representation of RSOM data, taken at Day 9 post injection, and correlation with cryo-slices the same tumor. MIP of
the volumetric RSOM data from a depth of A) 930 μm, B) 615 μm, C) 390 μm, and D) 0 μm to a depth of 2115 μm. E–G) correspondingly
show cryo-slices taken at a depth of 930 μm (E), 615 μm (F), and 390 μm (G). H) 3D visualization of the whole ROI. Arrows point to the
location of the tumor. Scale bar: (D) 1 mm, (G) 2 mm.
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